Consideration and Assessment of Patient Factors When Selecting an Inhaled Delivery System in COPD

Chest. 2024 Feb;165(2):323-332. doi: 10.1016/j.chest.2023.11.011. Epub 2023 Nov 15.

Abstract

Because guidelines and strategies for pharmacologic treatment of COPD focus on specific classes of inhaled medications, there is an unmet need for information to guide health care professionals for selecting an inhaled medication delivery system that matches the unique characteristics of individual patients. This article provides guidance for selecting an inhaled medication delivery system based on three "key" patient factors: cognitive function, manual dexterity/strength, and peak inspiratory flow. In addition, information is provided about specific tests to assess these patient factors. Cognitive impairment with an estimated prevalence of 25% among patients with COPD adversely affects patients' ability to correctly use a handheld device. To our knowledge, the prevalence of impaired manual dexterity/strength has not been reported in those with COPD. However, 79% of patients with COPD have reported one or more physical impediments that could influence their ability to manipulate an inhaler device. The measurement of peak inspiratory flow against the simulated resistance (PIFr) of a dry powder inhaler establishes whether the patient has the inhalation ability for creating optimal turbulent energy within the device. A suboptimal PIFr for low to medium-high resistance dry powder inhalers has been reported in 19% to 84% of stable outpatients with COPD. Health care professionals should consider cognitive function, manual dexterity/strength, and PIFr in their patients with COPD when prescribing inhaled pharmacotherapy. Impairments in these patient factors are common among those with COPD and can affect the individual's competency and effectiveness of using inhaled medications delivered by handheld devices.

Keywords: cognitive function; inhaler competency; manual dexterity and strength; peak inspiratory flow; prescribing inhaled pharmacotherapy; shared decision-making.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Bronchodilator Agents
  • Dry Powder Inhalers
  • Humans
  • Prevalence
  • Pulmonary Disease, Chronic Obstructive*

Substances

  • Bronchodilator Agents